BiOasis Raises C$1.7M from Warrants | GenomeWeb

NEW YORK (GenomeWeb News) – BiOasis Technologies today said that it will receive cash proceeds of C$1.7 million (US$1.4 million) from the exercise of warrants that expired on March 31.

The Vancouver, BC-based developer of therapeutics and molecular diagnostics for neurological diseases said that a result of the warrants being exercised it now has cash and cash equivalents of C$2.4 million. The additional funds will enable the firm to fund a final trial of the p97 biomarker as a diagnostic for Alzheimer's disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.